Bisphosphonate and statin: adverse effects of co-medication on wound healing in in vitro models of periodontal tissues

Read full text
Authors: Agnes Småland-Reksten, Anne Eriksson Agger, Aina M. Lian, Janne Elin Reseland, Tormod B. Krüger
Cited by: 2
References: 40

Abstract

OBJECTIVE: Bisphosphonates and statins may influence wound healing and are frequently prescribed to the same patient group. Bisphosphonates may induce osteonecrosis of the jaw; however, little information is available on the cellular mechanisms and biological effects of co-medication in oral tissues. The aim was to assess the effects of alendronate and simvastatin, both alone and combined, on osteoblasts and gingival fibroblasts in vitro. STUDY DESIGN: Primary human gingival fibroblasts and primary human osteoblasts were incubated with alendronate (5 µM) and simvastatin (1, 5 or 10 µM), alone or combined, for up to 14 days. Cells were assessed for viability by measuring lactate dehydrogenase activity and caspase-3 concentration in the cell culture media. Migration and proliferation potential was assessed by scratch-wound assay. Secreted levels of cytokines/chemokines were measured using Luminex 200 multianalytic profiling. RESULTS: High concentrations of simvastatin, both alone and combined with alendronate, affected the proliferation/migration potential and reduced scratch closure. The same exposure induced near abolishment of secreted levels of cytokines affecting angiogenesis, such as VEGF, IL-6, IL-8, and MCP-1, however little effect was found on cell viability. CONCLUSION: High concentrations of simvastatin, alone or combined with alendronate, may have a negative impact on angiogenetic markers and cell migration/proliferation, affecting wound healing and growth.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Cancer Lipids and Metabolism Bone health and treatments

Publication details

Journal / source
Acta Odontologica Scandinavica
Publisher
MJS Publishing, Medical Journals Sweden AB
Volume
85
Pages
125–133
Publication date
18 March 2026
Language
EN